USA flag logo/image

An Official Website of the United States Government

A NEW DRUG FOR DEPRESSION

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
61069
Program Year/Program:
2002 / SBIR
Agency Tracking Number:
MH063663
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AZEVAN PHARMACEUTICALS, INC.
116 RESEARCH DRIVE BETHLEHEM, PA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2002
Title: A NEW DRUG FOR DEPRESSION
Agency: HHS
Contract: 1R41MH063663-01A1
Award Amount: $100,000.00
 

Abstract:

Long Term Goals: Serenix Pharmaceuticals (SP) will develop drugs for the treatment of CNS disorders. Strategy: SP acquired a series of vasopressin receptor antagonists from Eli Lilly and Company and has refined these molecules through manipulations of various structural zones. A subset of these antagonists (LEAD SERIES) exhibit reasonable affinity for the vasopressin receptor subtype involved in depression and stress-related affective disorders. The LEAD SERIES requires refinement to optimize affinity (less than 5 .0 nM) and early stage testing to demonstrate biological activity. The platform molecule has four essential structural zones; two of these will be the focus of the proposed research. Phase I objectives are (i) utilize classical and combinatorial chemistry to modify structural zones on the LEAD SERIES to generate ca. 200 compounds, (ii) screen these for target receptor affinity and focus on those with Kds less than 5 nM, and (iii) test the high affinity compounds for in vitro biological activity. The findings, combined with considerations related to affinity, structural diversity, structural attractiveness, and QSAR models, will identify promising compounds for testing in Phase II for oral absorption, stability, metabolism, toxicity, and efficacy.

Principal Investigator:

Neal G. Simon
6107583620
NGS0@LEHIGH.EDU

Business Contact:

Simon Simon
6107583620
NGS0@LEHIGH.EDU
Small Business Information at Submission:

SERENIX PHARMACEUTICALS, INC.
SERENIX PHARMACEUTICALS, INC. 111 RESEARCH DR, B217 BETHLEHEM, PA 18015

EIN/Tax ID: 142167269
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No